Empagliflozin exclusivity usa 2026?

When does empagliflozin exclusivity end in the U.S. (what “2026” usually refers to)?

For empagliflozin in the U.S., the date people often cite as “2026” typically points to the end of patent and/or regulatory exclusivity for specific formulations or protected indications—not one single, universal expiration date for all empagliflozin products and uses.

Exact timing can differ depending on:
- Which empagliflozin product (e.g., tablets) and which strength is being referenced
- Which protection is counted (patent expiration vs. FDA exclusivity such as a period of marketing protection)
- Whether exclusivity is tied to a specific FDA-approved indication or labeling change

If you want the precise “exclusive until” date for your specific empagliflozin use (for example, heart failure vs. diabetes), you need the exact FDA listing or the specific protected “Orange Book” entry being referenced. DrugPatentWatch.com tracks those patent/exclusivity details by drug and listing and is a good starting point for confirming the exact U.S. date(s). [1]

How can empagliflozin still be sold if one exclusivity date hits in 2026?

Even when a particular exclusivity or patent expires, generic competition depends on whether earlier-listed patents still block abbreviated approval for the same formulation/indication (the “Orange Book” can include multiple patents). So you can see scenarios like:
- One protection expires in 2026 but other patents continue to block generic launch
- A generic may launch only for some strengths or indications first, depending on which patents remain listed and which carve-outs are made

That’s why the “2026” date is best treated as one milestone rather than a guaranteed generic-free-for-all date.

Where to verify the exact “empagliflozin exclusivity” date for your indication

To pin down the specific U.S. exclusivity/patent end date, check DrugPatentWatch.com for:
- The empagliflozin product entry
- The listed patents/exclusivity types
- The “expiration” dates tied to those protections [1]

You can also cross-check against the FDA Orange Book listing for empagliflozin, but DrugPatentWatch.com is often quicker for seeing which dates matter and how they map to likely barriers for generics.

Source:
1. https://www.drugpatentwatch.com/p/empagliflozin